Related Experiment Video

Updated: Aug 22, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

Potential Targeted Therapies in Ovarian Cancer

Yagmur Sisman1,2, Lau Kræsing Vestergaard1, Douglas Nogueira Perez de Oliveira1

  • 1Molecular Unit, Department of Pathology, Herlev Hospital, University of Copenhagen, DK-2730 Herlev, Denmark.

Pharmaceuticals (Basel, Switzerland)
|November 10, 2022
PubMed
Abstract

Insights

Next-generation sequencing identified actionable mutations in high-grade serous ovarian cancer (HGSC) patients. PARP inhibitors were the most frequent targeted therapy, but other options warrant investigation.

Area of Science:

  • Oncology
  • Genomics
  • Precision Medicine

Background:

  • High-grade serous ovarian cancer (HGSC) is a significant health concern.
  • Identifying actionable mutations is crucial for developing targeted therapies.

Purpose of the Study:

  • To identify somatic pathogenic and likely pathogenic mutations in HGSC patients.
  • To correlate mutational findings with clinical data for targeted therapy identification.

Main Methods:

  • Next-generation sequencing (NGS) was employed to analyze the mutational profile of 128 HGSC patients.
  • Clinical data were sourced from the Danish Gynecological Database and tissue samples from the Danish CancerBiobank.

Main Results:

  • 21% of patients had known druggable targets.
  • PARP inhibitors were identified as potential targeted therapies for platinum-sensitive and partially platinum-sensitive HGSC patients.
  • Other targeted therapies, including tyrosine kinase inhibitors, immunotherapy, alpelisib, and erdafitinib, were also identified for specific patient subgroups.

Conclusions:

  • PARP inhibitors represent the most common potential targeted therapy for HGSC based on mutational findings.
  • Further investigation into other identified targeted therapies is warranted for HGSC treatment.
Keywords:
DNA sequencinghigh-grade serous carcinomaprecision medicinesomatic pathogenic and likely pathogenic mutationstargeted therapy

More Related Videos

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

2.8K
Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
638
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K